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Abstract: Musculoskeletal conditions represent a considerable burden worldwide, and 
are predominantly managed in primary care. Evidence suggests that many musculoskeletal 
conditions share similar prognostic factors. Systematically assessing patient’s prognosis and 
matching treatments based on prognostic subgroups (stratified care) has been shown to be both 
clinically effective and cost-effective. This study (Keele Aches and Pains Study) aims to refine 
and examine the validity of a brief questionnaire (Keele STarT MSK tool) designed to enable 
risk stratification of primary care patients with the five most common musculoskeletal pain 
presentations. We also describe the subgroups of patients, and explore the acceptability and 
feasibility of using the tool and how the tool is best implemented in clinical practice. The study 
design is mixed methods: a prospective, quantitative observational cohort study with a linked 
qualitative focus group and interview study. Patients who have consulted their GP or health care 
practitioner about a relevant musculoskeletal condition will be recruited from general practice. 
Participating patients will complete a baseline questionnaire (shortly after consultation), plus 
questionnaires 2 and 6 months later. A subsample of patients, along with participating GPs and 
health care practitioners, will be invited to take part in qualitative focus groups and interviews. 
The Keele STarT MSK tool will be refined based on face, discriminant, construct, and predictive 
validity at baseline and 2 months, and validated using data from 6-month follow-up. Patient and 
clinician perspectives about using the tool will be explored. This study will provide a validated 
prognostic tool (Keele STarT MSK) with established cutoff points to stratify patients with the 
five most common musculoskeletal presentations into low-, medium-, and high-risk subgroups. 
The qualitative analysis of patient and health care perspectives will inform practitioners on 
how to embed the tool into clinical practice using established general practice IT systems and 
clinician-support packages.
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Background
Musculoskeletal conditions represent a considerable burden worldwide. The Global 
Burden of Disease study findings show that such conditions as low-back pain are 
the leading cause of years lived with disability in Western Europe and Australia, 
and that musculoskeletal conditions overall account for 6.8% of global disability-
adjusted life-years, comparable to cancer (7.8%), ischemic heart disease (5.2%), 
and mental disorders (7.4%).1 This burden is reflected in health care use: musculo-
skeletal consultations account for around a fifth of all consultations in UK primary 
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care.2,3 Prevalence of persistent musculoskeletal pain is 
high, estimated at 25%–32%,4 and recurrence is common.5 
Musculoskeletal conditions thus have a major impact on the 
individual, health care, and society.6
While regional musculoskeletal pain presentations (ie, 
pain specific to a certain body region) are recognized by 
virtue of the anatomical location (eg, back, neck, shoulder, 
knee) and associated features of such pain presentations (ie, 
impact on physical function), there is strong substantive 
evidence that pain presentations share common underly-
ing mechanisms.7 Co-occurrence of pain in different body 
regions is high,8 and risk of poor outcome is increased for 
those with multisite pain.9,10 Additionally, patients with differ-
ent regional musculoskeletal pains (eg, back, neck, shoulder, 
or knee pain) and those with multisite pain share similar 
prognostic factors.11–13 Previous work has demonstrated that 
a chronic pain-risk score, incorporating prognostic indicators, 
and developed in patients with back pain,14 is valid for use 
among patients with pain at different anatomical sites, and 
in different settings.15–17 Other work18 has shown that patients 
can be screened to assess the presence of prognostic factors, 
irrespective of the specific location of the musculoskeletal 
condition. However, previous methods and tools, such as the 
Örebro Musculoskeletal Pain Screening Questionnaire were 
not designed for use specifically within primary care19,20 or to 
stratify patients based on their level of risk and recommend 
matched treatments (stratified care). One model of stratified 
care is to create subgroups based on a prognostic profile.21 
This approach of stratified care can “fast-track” patients to 
the appropriate treatment by supporting clinical decision 
making, and has the potential to maximize treatment benefit, 
reduce harm, and increase health care efficiency.22
One prognostic tool (the STarT [subgroups for targeted 
treatment] Back tool) was successfully developed for low-back 
pain patients in primary care,23 specifically to assist in matching 
patients to different treatments. The tool consists of nine items, 
and utilizes cutoff point scores to identify three prognostic sub-
groups (low, medium, and high risk of persistent back-related 
physical disability). All physical and psychological prognostic 
indicators in the STarT Back tool were chosen based on their 
potential to be modifiable through treatment. Subsequent use of 
the tool, as part of a stratified care model in which subgroups 
of patients were matched to different treatments, has demon-
strated superior clinical and economic outcomes compared to 
best current practice and usual primary care.24,25
Given this promising research, the predictive ability of a 
modified, generic version of the STarT Back tool was tested 
in a broader range of patients with musculoskeletal pain 
presentations (neck pain, upper-limb pain, lower-limb pain, 
multisite pain, and back pain). The predictive performance of 
this new draft – “Keele STarT MSK tool” – was assessed in 
secondary analysis of two large data sets of patients with mus-
culoskeletal pain conditions consulting physiotherapy services 
(PhysioDirect study)26 and musculoskeletal primary–second-
ary care-interface services (SAMBA study).27 Results showed 
a moderate-to-good level of predictive ability of the draft tool 
in the identification of patients who developed persistent dis-
abling pain, eg, prediction of poor outcome using area under 
the curve (AUC) – back pain AUC 0.72, 0.79, neck pain AUC 
0.82, 0.88, upper-limb AUC 0.79, 0.86, lower-limb AUC 0.79, 
0.86, and AUC 0.83, 0.82 multisite pain – in PhysioDirect 
and SAMBA, respectively. However the results also indicated 
that different optimal cutoff points were required for different 
regional pain presentations (eg, lower limb, upper limb, spinal 
pain). Subsequent informal discussions on the applicability 
of the draft tool were carried out with GPs and first-contact 
health care practitioners (HCPs). Feedback from discussions 
indicated that due to the complexities of scoring the draft tool 
(ie, different cutoff points per body region) added to the current 
time pressures within primary care, a single generic tool with 
one set of cutoff points would be preferable in clinical practice. 
Furthermore, a more straightforward tool would facilitate links 
to matched treatments within a stratified care model.
The overall aims of the Keele Aches and Pains Study 
(KAPS) are further to refine and validate the draft Keele 
STarT MSK tool, and based on our previous experience 
in implementing stratified primary care for patients with 
low-back pain25 to collect information about the anticipated 
acceptability and feasibility of using such a tool, as well as 
identify barriers to implementation and practical solutions 
to these barriers.28 We aim to develop the tool for use with 
patients who have the five most common musculoskeletal 
pain presentations in primary care: back, neck, shoulder, 
knee, or multisite pain.3 The KAPS forms part of a larger 
National Institute for Health Research (NIHR) program of 
four linked work packages. The overall objective is to stratify 
patients with a range of musculoskeletal presentations based 
on risk of poor outcome, identify treatment options that are 
matched to each stratum, test the acceptability of this model 
in primary care, test whether such an approach is effective 
in the improvement of patient outcomes and experience, and 
test whether it is cost-effective.
Aims and objectives
Within the context of primary care and the five most com-
mon musculoskeletal presentations, there are two key aims 
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of the KAPS: 1) to refine and externally validate the draft 
Keele STarT MSK tool, and 2) to explore how such a tool 
might best be implemented within clinical practice. Specific 
objectives include:
•	 refine the Keele STarT MSK tool based on face, discrimi-
nant, construct, and predictive validity
•	 determine the tool risk-strata cutoff points based on 
optimal predictive values and suitability for matched 
treatment options
•	 estimate the proportions of patients classified at low, 
medium, and high risk of poor outcome and describe their 
characteristics, including patient health care utilization 
and costs and health-related quality of life
•	 examine the validity of a refined tool (predictive, external 
validation)
•	 explore clinicians’ perspectives on the acceptability 
and “added value” of stratified care based on progno-
sis  compared to current primary care management of 
patients
•	 explore patients’ perspectives about stratified primary 
care based on prognosis (eg, patient subgrouping using 
the tool, matched treatment options)
•	 identify clinicians’ and patients’ perceived barriers and 
solutions to using the draft Keele STarT MSK tool and 
matched treatment options in clinical practice.
Methods/design
Ethical approval for this study has been granted by the South 
East Scotland Research Ethics Committee in the UK (14/
SS/0083).
Study design and setting
This will be a prospective observational cohort study with a 
linked qualitative study within a primary care setting.
Participating patients
Consecutive adult patients who visit their GP with one (or 
more) of the five most common musculoskeletal pain presen-
tations – back, neck, shoulder, knee, or multisite pain – will 
be invited to participate in the cohort study. A subsample of 
patients who respond and agree to participate in the cohort 
study will be invited to take part in the linked qualitative 
focus groups and interviews. In addition, GPs and other HCPs 
involved in musculoskeletal treatments (eg, physiotherapists) 
will be invited from the participating general practices and 
related services, or known clinical networks, to take part in 
focus groups and interviews.
Inclusion/exclusion criteria
Inclusion criteria are patients registered at participating 
general practices, aged 18 years or over, consulting with the 
included musculoskeletal pain presentations, and able to 
read and understand English. All consecutive patients will 
be invited to participate, regardless of prior consultations. 
Exclusion criteria are indication of serious pathology (eg, 
suspected fracture, cancer), inflammatory arthritis, crystal 
disease, spondyloarthropathy, polymyalgia rheumatica, 
pregnancy-related pain problems, urgent cases (eg, cauda 
equina syndrome), or vulnerable patients (eg, experienced 
recent trauma, cognitive impairment, dementia, or terminal 
illness). There are no inclusion/exclusion criteria for the GP 
and other HCP focus groups and interviews, but researchers 
will attempt to recruit to maximize sample variation on the 
basis of age, sex, clinical experience, location, and clinical 
specialty. All focus groups will be conducted in English.
Cohort study recruitment
Individual patients who consult with back, neck, shoulder, 
knee, or multisite pain will be identified through relevant 
musculoskeletal symptom and diagnostic Read codes. 
The Read codes have been previously used by Jordan et 
al,3 with additional amendments and checks for relevance 
and completeness carried out by GPs in the research team. 
GP practice staff and Clinical Research Network staff will 
support weekly-to-fortnightly electronic record searches 
for the relevant Read codes at participating primary care 
practices to identify potentially eligible patients. Patients’ 
GPs will be invited to screen patient lists prior to mail-
ing. Eligible patients will receive an invitation letter 
and survey pack (participant information sheet, baseline 
questionnaire, and prepaid return envelope) from their 
GP shortly after their musculoskeletal pain consultation 
(index consultation).
Return of the completed questionnaire by the patient will 
signify consent to participate in the cohort study (ie, consent 
to receive further questionnaires), as specified within the 
participant information sheet. In addition, specific consent 
will be requested to allow access to patients’ medical records 
and to be contacted about further linked research (ie, linked 
qualitative focus groups and interviews). Baseline nonre-
sponders will be sent a reminder postcard after 2 weeks and 
a reminder letter (with a copy of the baseline questionnaire) 
2 weeks after that. Patients who indicate that they do not 
wish to take part at any point will not be sent any further 
correspondence. Patients will not receive any payment or 
financial incentive to take part.
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Cohort study follow-up
All patients who have signified consent to take part will be 
sent follow-up questionnaires 2 months and 6 months after 
baseline. Wording on each follow-up questionnaire will be 
personalized to indicate which anatomical area they originally 
consulted about during their index consultation (ascertained 
from patients’ baseline questionnaire responses). One week 
before follow-up questionnaire mailing, patients will receive 
a reminder (pre-follow-up) that they are about to receive 
their next questionnaire. After the 2-month and 6-month 
questionnaire mailing, nonresponders will receive a reminder 
after 2 weeks (postcard, text message, or email), and a repeat 
questionnaire 2 weeks later. After the final 6-month mail-
ing, a brief questionnaire containing only the key-outcome 
measures (minimal data collection [questionnaire]) will be 
sent at 6 weeks to nonresponders. Finally, telephone contact 
will be attempted at 8 weeks for those who have provided a 
telephone number on their baseline questionnaire, to collect 
key-outcome data (minimal data collection [telephone]). 
Telephone calls will be carried out by a research nurse. 
Please see Figure 1 for a flowchart of the recruitment stages 
for the KAPS.
The recruitment strategies outlined follow a recent 
Cochrane review of best practice to increase response to 
postal questionnaires,29 and follow guidelines from the World 
Health Organization for research to adapt to the rapid changes 
in the way people communicate (eg, mobile technologies, 
telephone communication, Internet).30
Cohort study data collection
The draft Keele STarT MSK tool and the key primary 
quantitative measures will be included in the questionnaire 
measures at all time points. The key primary quantitative 
measures are physical health (short-form [SF]-36 version 2 
physical component summary score),31,32 pain-intensity (least, 
average, and current pain),33 and pain interference (Promis 
pain-interference scale).34 The study will also include a mea-
sure of health-related quality of life (EuroQol [EQ]-5D-5L)35 
at all time points. The minimal data-collection questionnaire 
will include the SF-12, which is a shortened version of the 
SF-36 version 2.36 Secondary measures include aspects of 
pain duration, spread and bother, self-reported change in 
symptoms (follow-up stages only), pain catastrophizing, pain 
self-efficacy, illness perceptions, sleep problems, physical 
activity, social support, health literacy, comorbidity, employ-
ment status, and factors about employment if applicable 
(see Table 1 for full list of measures, references, and time 
points for data collection). There will also be questions in 
the follow-up questionnaires on previous National Health 
Service (NHS) and non-NHS health care utilization (eg, 
contact with GP, nurse, physiotherapist, osteopath, and use of 
X-rays, surgery, prescriptions, over-the-counter medication). 
In addition, single-item questions derived and adapted from 
the established measures outlined will be included. The selec-
tion of these items is based on their prognostic performance 
in primary care musculoskeletal pain studies.37–40
Cohort study medical record review
For those who give consent, analysis of medical records will 
supplement patient self-report information (eg, additional 
information on prescriptions, consultation frequency, referral 
for further treatment, diagnostic tests, and sickness certifi-
cation/fit notes). The time scale for medical record review 
is 1 month prior to the patient’s index consultation, up to 6 
months after their index consultation.
Cohort study sample size
Based on a 6-month recruitment period at each participating 
practice, from a source population of approximately 40,000 
registered adult patients with an estimated annual consulta-
tion prevalence of 20% for musculoskeletal consultations,3 
we estimate that there will be approximately 3,000 eligible 
patients who consult with the five most common musculo-
skeletal pain presentations during the recruitment period. 
With an estimated response of 60%–70% (based on previous 
studies with similar populations),33,41 we anticipate recruit-
ing 1,800 patients at baseline and retaining 1,250 patients at 
6-month follow-up. Calculations show a minimum of 100 
patients per outcome category (risk subgroup) is required 
for external validation.42 Based on our previous studies,23–26 
we anticipate that at least 10% of musculoskeletal patients in 
primary care will be classified at high risk of poor outcome 
(the smallest risk stratum), and thus each risk subgroup 
will include at least 125 follow-up respondents, providing 
adequate power for validation of the draft Keele STarT MSK 
tool using data from 6-month follow-up.
Cohort study analysis
Refining the Keele STarT MSK tool and evaluating its valid-
ity will be carried out in four stages. First, the performance 
of the draft tool will be described. Patients will be classi-
fied, using the draft tool (including cutoff points based on 
the original STarT Back tool, ie, total score <4, “low risk”; 
total score ≥4 and psychosocial subscale score <4, “medium 
risk”; total score ≥ 4 and psychosocial-subscale score ≥4, 
“high risk”), as being at low, medium, or high risk of poor 
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outcome.23 They will be described in terms of their base-
line characteristics: pain (pain intensity, pain interference, 
pain bother), physical function (SF-36 version 2 physical 
component score [PCS]), mental health (SF-36 version 2 
mental component score), general health (SF-36 version 
2, sleep problems, fatigue, physical activity, comorbidity), 
psychological reactions to pain (coping strategies, pain self-
efficacy, illness perceptions), quality of life (EQ-5D-5L), 
health literacy (single-item literacy screener), and social 
factors (eg, available emotional and instrumental social sup-
port, employment status, socioeconomic status). This will 
allow assessment of the draft tool’s discriminant validity, ie, 
Figure  1 Flowchart of recruitment procedure for the Keele Aches and Pains Study.
Patient index consultation with
GP practice
Relevant Read code flagged on 
practice system
GP system searched for
eligible participants (e.g. eligible
Read code)
GP invited to screen eligible patient list
Eligible participant mailed study
pack
No response to baseline mailing – postcard
reminder (2 weeks), reminder letter and copy
of baseline questionnaire (4 weeks)
Patient returns baseline
questionnaire, signifying consent to
take part in follow-up phases
Subsample of patients invited to take part in
focus groups
Invitation to GPs and other health care
professionals to take part in focus groups 
Participants mailed pre-follow-up
reminder (1 week prior). Mailed
2-month follow-up questionnaire
No response to 2-month mailing – reminder
(2 weeks), reminder and copy of 2-month
questionnaire (4 weeks) 
Participants mailed pre-follow-up
reminder (1 week prior). Mailed
final 6-month follow-up
questionnaire
No response to 6-month mailing – reminder
(2 weeks), reminder and copy of 6-month
questionnaire (4 weeks), minimal data – postal 
collection (6 weeks), minimal data – telephone 
call (8 weeks)
Participants who agreed to
medical record review 
Review of consenting 
participants’ medical records at the
end of the 6-month mailing stage
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ability to discriminate between low-, medium-, and high risk 
subgroups. Hypotheses will be tested based on the assump-
tion that participants in medium- and high-risk subgroups 
will have higher pain intensity,54 more pain bother, poorer 
physical function, and lower levels of physical and mental 
health. Evaluation will be based on analysis of variance using 
linear constraints for numerical measures and the c2 test for 
trends for comparing and testing associations in categori-
cal outcome measures. In order to assess construct validity, 
risk subgrouping based on the draft tool will be compared 
with classification based on the Örebro Musculoskeletal 
Pain Screening Questionnaire,20 an existing tool for the 
prognostic classification of patients with musculoskeletal 
conditions (medium and high scores will be combined for 
purposes of this comparison). In the subsample of partici-
pants with low-back pain, comparisons will also be made 
with risk classification according to the STarT Back tool. 
The results will be expressed as percentage agreement and 
weighted k-values with 95% confidence intervals. Test of 
linear association will also be given by the c2 test for trend.
The predictive performance of the draft Keele STarT 
MSK tool will be investigated by assessing the ability of 
the tool to predict outcome at the 2-month follow-up. It is 
hypothesized that participants with lower baseline scores (ie, 
those at “low” risk (or “medium” risk compared to “high” 
risk) will have better outcomes. Evaluation will be based on 
analysis of variance using linear constraints for numerical 
2-month measures, and the c2 test for trends for comparing 
and testing associations in categorical 2-month outcome 
measures. In relation to the key outcomes of physical health 
(SF-36-PCS), predictive performance of the draft tool will 
be expressed in terms of percentage of variance explained 
(parametric and nonparametric Nagelkerke R2), calibration 
(calibration slope and Hosmer–Lemeshow test), and area 
under the receiver-operating characteristic curve (C-statistic) 
via receiver-operating-characteristic analysis for discrimina-
tion, including dichotomies for the SF-36-PCS based on 
lower tertiles extracted from a similar cohort,26 ie, 37.17 and 
39.61 at 2- and 6-month follow-up, respectively.55,56 A replica-
tion of this analysis using the SF-36-PCS will be carried out 
for pain intensity (eg, a score of 5 or more denotes moderate/
severe pain).57 In addition, as a sensitivity analysis, variation 
in performance will be examined across participants with 
different index pain sites.
Table 1 Outcome domains, measures, and timing of data collection
Domain Measure Questionnaire stage
Physical health SF-36 version 2, physical component summary score31,32 All questionnaires
Pain interference Promis Pain Interference Scale34 All questionnaires
Pain intensity Pain intensity33 All questionnaires
Pain location Pain location, body mannequin43 Baseline
Pain experience Spread and duration of pain33,44 Baseline
Quality of life EQ5D-5L35 All questionnaires
NHS and non-NHS health care 
utilization
Questions on primary and secondary health care contacts, investigations, treatments, 
medications, self-certification
2-month follow-up
6 month follow-up
Health literacy Single-item literacy screener45 Baseline
Psychological reactions to pain Coping Strategies Questionnaire (catastrophizing subscale,46 Pain Self-Efficacy 
Questionnaire,47 selected items – revised Illness Perception Questionnaire48,49
Baseline
6-month follow-up
Sleep Jenkins Sleep Questionnaire50 All questionnaires
Fatigue SF-36 vitality scale32 All questionnaires
General health SF-36 general health scale version 231,32 All questionnaires
Mental health SF-36 version 2 mental component summary score31,32 All questionnaires
Physical activity Single question on physical activity51 All questionnaires
Change since index consultation Global rating of change question – single item11,52 2-month follow-up
6-month follow-up
Comorbidity Presence of other long term medical conditions Baseline
Social support Emotional and instrumental support53 Baseline
Employment Employment status, work loss, work satisfaction Baseline
6-month follow-up
Screening tool comparison Örebro Musculoskeletal Pain Screening Questionnaire short form,20 STarT Back tool23 Baseline
Risk of persistent disabling pain Draft Keele STarT MSK tool All questionnaires
Education Years in full-time education, further education, qualifications Baseline
Medical record review General practice records of consultation frequency, prescriptions, referrals, diagnostic 
tests, sickness/fit notes
NA
Minimal data collection Pain intensity,33 SF-12,36 global rating of change question – single item11,52 Minimal data collection
Abbreviations: EQ, EuroQol; SF, short form; STarT, subgroups for targeted treatment; NA, not applicable.
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Second, opportunities to refine and improve upon the draft 
Keele STarT MSK tool will be investigated. In particular, 
face and content validity, completion rates, and predictive 
performance of the tool will be optimized by the inclusion 
of additional or alternative items or the removal of items. 
Predictive performance will be assessed against physical 
health (SF-36-PCS) and pain-intensity scores at 2-month 
follow-up. Primary evaluation will use the whole sample, 
but sensitivity analyses will be carried out for participants 
with pain at each index site. A number of single-candidate 
item questions will be included in baseline questionnaires 
(physical, psychological, or social factors); these are based on 
an updated review of prognostic factors for musculoskeletal 
pain in primary care, overview of other comparable tools 
(Örebro and Von Korff risk score), and examination of other 
questions used to measure the same and/or other identified 
key domains. As with the development of the Keele STarT 
Back tool,23 all candidate items will be potentially modifiable 
by treatment. This analysis will be carried out in stages by 
substituting, adding, or removing one item at a time. Deci-
sions about whether to change, add, or remove an item will be 
based on all available information (face and content validity, 
item-completion rate, and predictive performance overall and 
across pain sites). For example, if swapping one item in the 
draft tool for a new candidate item with better face validity 
leads to similar item-completion rates and improves predic-
tive performance compared to the draft tool, a decision would 
be made to remove the existing item and add the new item.
The refined tool will then be investigated to see whether 
it is exhaustive by checking whether items reflecting dif-
ferent domains can be added to improve predictive validity 
substantially. In addition, the potential for item redundancy 
will be examined by reviewing the tool’s predictive perfor-
mance versus simplification by exclusion of single items one 
at a time. At all stages, the main focus will be on improved 
predictive performance across the total study population, 
but review of predictive validity will also be extended to 
individual index pain sites, and face and construct validity 
will be taken into account.
The third step is to identify tool risk-strata cutoff points. 
Two approaches will be considered. One approach will 
identify the optimal cutoff points on the 0–9 scale that strati-
fies the population into three subgroups of low, medium, 
and high risk based on evaluation of sensitivity/specificity, 
predictive values (positive/negative), and likelihood ratios 
(positive/negative) against clinical thresholds for the SF-
36-PCS and pain, as detailed earlier. An alternative method 
used in the development of the STarT Back tool23 is based 
on a separate cutoff point using a psychosocial subscale to 
identify complex patients. In this approach, items that could 
be classified as key in identifying patients who are at high 
risk (ie, psychosocial, complex problems) will be identi-
fied. These two approaches to defining cutoff points will be 
compared in terms of discriminant, construct, and predictive 
validity (as described in steps 1 and 2) and reviewed by the 
study team for feasibility and fit.
The fourth and final stage is to determine whether the 
refined version of the tool has external validity. This will be 
done by assessing the discriminant, construct, and predictive 
validity of the refined tool against 6-month outcomes. In 
addition, these same analyses will be conducted following 
multiple imputation of missing data to assess robustness of 
the tool’s properties. At all stages of the analysis, a clinical 
advisory group and user representatives (patient and public 
involvement of people with similar musculoskeletal con-
ditions) will be consulted about the draft versions of the 
Keele STarT MSK tool, and any suggested changes will be 
discussed, to ensure acceptability, face validity, and clinical 
utility of the final screening tool, cutoff points, and identi-
fied risk strata.
Current health care and treatments for the whole cohort 
by risk strata and by pain site will be described using data 
from patient self-report questionnaires at 6 months. NHS 
and non-NHS resource use will be multiplied by unit costs 
obtained from standard sources, in order to calculate mean 
overall per patient costs and by broad health care-resource 
use type. A description of mean costs by risk strata and by 
pain site will be presented. Responses to the EQ-5D-5L will 
provide estimates of mean quality of life (utility) values, again 
for the whole patient group and by risk strata and pain site.
Qualitative study
Focus groups will be conducted with patients, GPs, and other 
HCPs. The key aims of the focus groups for GPs and HCPs are 
to investigate clinicians’ perspectives on the “added value” of 
prognostic stratified care to current primary care management 
of patients who consult for musculoskeletal conditions and to 
identify practical implications of embedding the Keele STarT 
MSK tool within consultations that complement existing 
diagnostic approaches. For patients, the key aim is to explore 
their views on the most acceptable ways of communicating 
prognostic screening results and the understanding of a strati-
fied model of care. For both GPs/HCPs and patients, there 
is also the aim of understanding any potential barriers and 
exploring practical solutions to the use of stratified care. If 
difficulty is experienced in recruiting an adequate number 
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for the focus groups, we will conduct one-to-one interviews 
(face to face or over the telephone) with respondents who have 
expressed an interest in taking part, but have not been able 
to attend any of the arranged focus groups, and who agree to 
this alternative data-collection method.
Patient focus groups (and interviews)
A subsample of patients who have responded to the cohort 
baseline questionnaire, given consent to further contact, and 
provided telephone contact details will be invited to take part 
in a focus group. Patients will be purposively sampled to 
obtain a sample with diverse characteristics; including, age, 
socioeconomic status, and reported pain site/severity. Such 
information will be obtained from patients’ participation 
and information given in the cohort study questionnaire. 
We plan to convene approximately two patient focus groups 
(up to eight patients per group), but the final number will 
be determined by “data saturation” (if all themes have been 
explored in sufficient depth). Patients who express inter-
est in taking part will be posted a formal invitation letter 
and participant information sheet. After sufficient time 
(approximately 2–3 days) for potential participating patients 
to receive and read the information and to decide whether 
or not to take part, patients will receive a further telephone 
call/s to confirm agreement and make arrangements. A date 
will be agreed upon, based on convenience to all patients 
and researchers, and a final confirmation letter of the date, 
time, and venue (including directions and map) will be 
sent to participating patients by post. Patient focus groups 
(and interviews) will be convened at a convenient location 
and setting, such as Keele University or another potential 
venue, such as a GP practice, other local NHS site, or the 
patient’s own home. Written consent will be obtained prior 
to the focus group discussion or one-to-one interview (as 
appropriate). Patients who agree to a telephone interview 
will receive a consent form along with their confirmation 
letter, and will be instructed to return it to the study team 
within a prepaid envelope.
General practitioner focus groups (and interviews)
We will invite GPs from participating practices plus GPs from 
known clinical networks to attend a focus group. Although 
no purposeful sampling will take place for the recruitment of 
GPs or HCPs, the study will consider a range based on experi-
ence levels and length of time in practice, as well as varying 
degrees of familiarity with a prognostic approach to stratified 
care for low-back pain. We will hold approximately four focus 
groups (up to eight GPs per group), though the final number 
will depend on data saturation. One-to-one interviews either 
face to face or via the telephone will be carried out as appro-
priate (where recruitment to focus groups has not provided 
an adequate sample size) and where practically possible for 
GPs who cannot attend a focus group. Focus groups will be 
held at Keele University or alternatively at one or more of the 
participating practices, dependent on preferences. One-to-one 
interviews will be conducted at a location convenient to the 
participating GPs, such as their practice. All GPs invited to 
take part will receive invitation letters and information sheets. 
Written consent will be obtained immediately prior to the 
focus-group discussion (or interview).
Health care professional focus groups (and 
interviews)
Approximately two focus groups will be convened with 
other HCPs (eg, such specialists as orthopedic surgeons, pain 
specialists, rheumatologists, and physiotherapists). However, 
the final number of focus groups will be dictated by data 
saturation. HCPs will be recruited from the services linked to 
participating GP practices and other known clinical networks. 
All HCPs will receive an invitation letter and information 
sheet, and written consent will be obtained immediately prior 
to the focus-group discussion (or interview). Focus groups 
(and one-to-one interviews) will be convened at either Keele 
University or at a convenient NHS or community venue.
Data collection
Each focus group will be convened in a similar way. First, a 
short presentation by the study team, including a summary 
and explanation of stratified primary care, will be delivered, 
followed by questions from participants in the focus groups. 
The presentation will include examples (vignettes) of how 
the Keele STarT MSK tool might be used in clinical practice 
and how patients might be classified into low-, medium-, 
and high-risk subgroups. Following the vignettes, there 
will be group discussion based on the topic guide, where 
participants will discuss each case scenario and share their 
views of the advantages and disadvantages, as well as the 
added value, face validity, acceptability, and appropriateness 
of stratified care for their particular pain problem (in the 
case of patients), and for use within clinical practice (for 
GPs/HCPs). One-to-one interviews will follow the same 
process, with a short explanation of stratified primary care, 
presentation of vignettes, and discussion based on the topic 
guide. Key emergent insights will be incorporated into the 
topic guides and explored in subsequent focus groups and 
interviews. This process is common to qualitative research, 
and facilitates the development of new insights not hitherto 
anticipated.
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Sample size
For patients, we anticipate a 50% response rate, and so will 
contact approximately 32 patients, with the aim of 16 patients 
agreeing to take part in focus groups or interviews. We aim 
to recruit to four GP focus groups (up to eight per group, so 
a total of up to 32 GPs) and two HCP groups (up to eight per 
group, so a total of 16 other HCPs).
Study analysis
Focus-group and interview data will be transcribed and coded 
thematically using NVivo qualitative data-management soft-
ware. Members of the research team, including social scientists 
and clinicians, will independently code a sample of the tran-
scriptions and discuss their interpretations at regular meetings. 
Each focus group and interview will be analyzed thematically 
in search of similarities and differences in clinicians’ and 
patients’ views about the face validity, acceptability, and added 
value of prognostic screening linked with matched treatment 
options in the care of patients with musculoskeletal pain.
The qualitative data will in turn be analyzed in search of 
common themes using the constant comparative method,58 
in order to identify the perceived barriers and solutions to 
using stratified care in clinical practice for the management 
of patients with the five most common musculoskeletal pain 
presentations. Specifically, the analysis of focus-group and 
interview data will be underpinned by Michie et al’s59 “theo-
retical domains framework”, previously applied to behavior 
change and implementation in health care settings.60,61 The 
framework contains 14 domains, including social, psycho-
logical, behavioral, and environmental, across which we will 
map the qualitative findings to determine the most salient 
influences on the potential for adoption of stratified primary 
care in practice. The analysis of the domains will help to 
identify the key barriers and enablers to stratified care, and 
identify key attributes (eg, skills, beliefs, knowledge, profes-
sional identity, environmental context), in order to address 
barriers or facilitate key enablers to change in future phases 
of the wider program of our research.
KAPS timeline
Baseline recruitment to KAPS is planned for 6 months at 
each participating GP practice, each participant will then be 
followed up for 6 months. After completion of follow-up, 
final data cleaning and analysis is planned.
KAPS data archiving and data access
The study is designed so that any participant personal data 
(eg, names, addresses) will be stored in a confidential, 
password-protected database accessible only by those with 
permission (eg, study team). Furthermore, all data used for 
analysis will be kept separate from participant personal data. 
Similarly, all hard-copy information (eg, signed consent 
forms, questionnaires) will be stored securely within the 
Arthritis Research UK Primary Care Centre building at Keele 
University. Hard-copy material will be stored for a period of 
5 years after the full NIHR program has completed (5-year 
period for program). After that period, all hard-copy mate-
rial will be destroyed. All confidentiality arrangements will 
adhere to relevant regulations and guidelines (Data Protection 
Act 1998, Caldicott review, General Medical Council, Medi-
cal Research Council, Research Governance Framework), and 
the chief investigator and study statistician (data custodian) 
will have responsibility to ensure the integrity of the data and 
that all confidentiality procedures are followed.
In certain circumstances, we can share access to our 
research databases to support joint publications and other 
research collaborations. Researchers wanting to apply for 
access to individual patient data from studies hosted by the 
Arthritis Research UK Primary Care Centre should complete 
an external data-request form and send an electronic version 
of the form, together with an outline design of the investiga-
tion and a short CV for all study team members external to 
the Arthritis Research UK Primary Care Centre. In the first 
instance, please contact primarycare.datasharing@keele.ac.uk.
KAPS oversight arrangements
This study is part of a larger NIHR program of work (grant 
RP-PG-1211-20010), and receives input from a dedicated 
program steering committee (PSC). The PSC consists of an 
independent chair, independent research and clinical mem-
bers, and also lay members (patient and public involvement). 
The PSC gives an independent perspective to the study and 
study processes, and ensures the study is conducted in accor-
dance with research governance inclusive of adherence to 
protocol, procedures of consent, and patient safety.
Discussion
This study aims to provide a validated prognostic tool (Keele 
STarT MSK tool), supported by information from patients and 
clinicians about likely acceptability and feasibility of use. The 
tool will enable the identification of different subgroups of 
patients seeking primary care for the five most common pain 
presentations (back, neck, shoulder, knee, multisite pain). The 
study will describe the patients within each risk subgroup, in 
terms of their clinical characteristics and health care use over 
a 6-month period after consultation. The tool is a starting point 
for a new stratified primary care model in which patients with 
these musculoskeletal pain presentations will be subgrouped 
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based on prognostic risk for matched treatment. We anticipate 
further testing, validation, and translation of the tool from 
varied research groups on different musculoskeletal treatment 
settings (eg, interface clinics, private practice, osteopathic 
practice, chiropractic practice), as has been demonstrated 
by the STarT Back tool’s subsequent development. Further 
investigation of this new Keele STarT MSK tool will be 
required on the added value within clinical decision making, 
and prediction stability will require further assessment within 
potential subgroups and different musculoskeletal popula-
tions (eg, age, sex, cultural variation, socioeconomic status, 
illness duration, diagnosis category). Currently, the tool is 
also being used within a planned randomized cluster trial, 
which is investigating if stratified care, involving the use of 
the Keele STarT MSK tool and matched treatment options for 
adults who present to GPs with one of the five most common 
musculoskeletal pain presentations, is more clinically effec-
tive and cost-effective compared to usual unstratified care.
While this protocol describes a comprehensive plan to 
develop and produce a validated prognostic tool, there are 
some limitations. Certain compromises have been made to 
minimize participant burden with regard to the questionnaire 
at baseline and follow-up, eg, we have used single-item or 
shortened-version measures for such aspects as physical 
activity and illness perceptions, whereas full versions would 
yield much more informative data.
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